

Amendments to the Claims

This listing of claims will replace all previous listing of claims

1. (Original) A dry powder formulation for inhalation, comprising active particles and carrier particles for supporting the active particles, the formulation-further comprising magnesium stearate in an amount of at least 0.5% by weight of the formulation, wherein particles of magnesium stearate are disposed on the surface of the carrier particles to provide a surface coverage of less than 10% on the carrier particles.

2. (Original) The dry powder formulation according to claim 1, wherein the surface coverage of carrier particles is from 1 to 5%.

3. (Original) The dry powder formulation according to claim 1, wherein the magnesium stearate is present in amounts of 0.5 to 2% by weight.

4. (Original) The dry powder formulation according to claim 1, wherein the magnesium stearate is present in amounts of form 0.6 to 1% by weight.

5. (Original) The dry powder formulation according to claim 1, wherein the active particles comprise an active substance selected from the group consisting of beta-mimetics, anticholinergics, corticosteroids, leukotrienantagonists, phosphodiesterase inhibitors, PAF-inhibitors, potassium channel openers, analgesics, potency agents, macromolecules, pharmaceutically acceptable salts thereof and mixtures thereof.

6. (Original) The dry powder formulation according to claim 1, wherein the carrier particles comprise a carrier material selected from monosaccharides, disaccharides, sugar alcohols, polylactic acid, or mixtures thereof.

7. (Original) The dry powder formulation according to claim 6, wherein the carrier is lactose mono-hydrate.

8.-11. (Cancelled)

12. (Original) The dry powder formulation according to claim 5, wherein the beta-mimetic is selected from the group consisting of Levalbuterol, Terbutalin, Reproterol, Salbutamol, Salmeterol, Formoterol, Fenoterol, Clenbuterol, Bambuterol, Tulobuterol, Broxaterol, Epinephrin, Isoprenaline and Hexoprenaline.

13. (Original) The dry powder formulation according to claim 5, wherein the anticholinergic is selected from the group consisting of Tiotropium, Ipratropium, Oxitropium and Glycopyrronium.

14. (Original) The dry powder formulation according to claim 5, wherein the corticosteroid is selected from the group consisting of Butixocart, Rofleponide, Budesonide, Ciclosenide, Mometasone, Fluticasone, Beclomethasone, Loteprednol and Triamcinolone.

15. (Original) The dry powder formulation according to claim 5, wherein the leukotrienantagonist is selected from the group consisting of Andolast, Iralukast, Pranlukast, Imitrodast, Seratrodast, Zileuton, Zafirlukast and Montelukast.

16. (Original) The dry powder formulation according to claim 5, wherein the phosphodiesterase-inhibitor is selected from Filaminast or Piclamilast.

17. (Original) The dry powder formulation according to claim 5, wherein the PAF-inhibitor is selected from the group consisting of Apafant, Forapafant and Israpafant.

18. (Original) The dry powder formulation according to claim 5, wherein the potassium channel opener is selected from Amiloride or Furosemide.

19. (Original) The dry powder formulation according to claim 5, wherein the analgesic is selected from the group consisting of Morphine, Fentanyl, Pentazocine, Buprenorphine, Pethidine, Tilidine, Methadone and Heroin.

20. (Original) The dry powder formulation according to claim 5, wherein the potency agent is selected from the group consisting of Sildenafil, Alprostadil and Phentolamine.

USSN: 10/575,656

Applicants: Muller-Walz

21. (Original) The dry powder formulation according to claim 5, wherein the macromolecule is selected from the group consisting of proteins, peptides, oligopeptides, polypeptides, polyamino acids, nucleic acids, polynucleotides, oligo-nucleotides and high molecular weight polysaccharides.

22. (Original) The dry powder formulation according to claim 6, wherein the monosaccharide or disaccharide is selected from the group consisting of glucose, lactose, lactose monohydrate, sucrose, trehalose and mixtures thereof.

23. (Original) The dry powder formulation according to claim 6, wherein the sugar alcohol is selected from mannitol, xylitol, or a mixture thereof.